Richard G. Stock, MD, presented “Combining Brachytherapy with SBRT” during the 26th Annual Southwest Prostate Cancer Symposium conference on April 14, 2023, in Scottsdale, Arizona.
How to cite: Stock, Richard G. “Combining Brachytherapy with SBRT.” April 14, 2023. Accessed Feb 2026. https://grandroundsinurology.com/combining-brachytherapy-with-sbrt/
Combining Brachytherapy with SBRT – Summary
Dr. Richard G. Stock explores the efficacy and potential benefits of combining brachytherapy with stereotactic body radiotherapy (SBRT) for prostate cancer treatment. He asserts that brachytherapy, known for its precision in delivering high doses of radiation directly to the tumor with minimal exposure to surrounding tissues, complements SBRT’s ability to target cancer cells with extreme accuracy over a few sessions. He posits that this combination maximizes tumor control while potentially reducing the overall treatment time and side effects compared to conventional radiation therapy.
Dr. Stock references data indicating improved biochemical control and decreased rates of late toxicity when brachytherapy is used in conjunction with SBRT. He underscores the importance of individualized treatment plans and patient selection criteria for optimizing outcomes, considering factors such as tumor stage, patient’s overall health, and previous treatments.
About the 26th Annual Southwest Prostate Cancer Symposium:
This conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Richard G. Stock, MD, is a Professor of Radiation Oncology at Mount Sinai in New York, New York. Dr. Stock’s clinical interests include cancers of the bladder, prostate, testis, and bone. His research focuses on prostate cancer and prostate brachytherapy. Dr. Stock is best known for establishing a comprehensive prostate cancer database with a corresponding IRB approved protocol to track treatment outcomes following prostate cancer therapies.
